AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 26561733
Drug: Guided Internet-delivered
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guided Internet-delivered cognitive behaviour therapy (ICBT)
Trial: 10568679
Drug: Gemcitabine 1000
RxNorm normalized name: gemcitabine 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine 1000 mg/m2 (30-min intravenous infusion on days 1, 8, 15 of a 28-day cycle)
Trial: 10568679
Drug: Cisplatin 100
RxNorm normalized name: CISPLATIN 100MG/VIL (PF) INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin 100 mg/m2 (day 1) and etoposide 100 mg/m2 (days 1, 2, 3)
Trial: 9092418
Drug: Platelet antiaggregants
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platelet antiaggregants (aspirin and ticlopidine)
Trial: 9092418
Drug: Anticoagulants (heparin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticoagulants (heparin, vitamin-K antagonists)
Trial: 1988398
Drug: Teaching, treadmill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teaching, treadmill exercise testing, and exercise training (three times weekly for 5 weeks)
Trial: 7049189
Drug: Clofibate (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clofibate (1.5 g daily for 10 days)
Trial: 22101095
Drug: Intratympanic gentamicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intratympanic gentamicin (ITG) - buffered gentamicin solution injected in the middle ear (maximum of 2 injections)
Trial: 22101095
Drug: Intratympanic dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intratympanic dexamethasone (ITD) - 4 mg/mL, 3 injections at intervals of 1 every 3 days
Trial: 18192544
Drug: AIR inhaled
RxNorm normalized name: air
DrugBank: Medical air (DB09337)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AIR inhaled insulin (12 units)
Trial: 18192544
Drug: Subcutaneous insulin
RxNorm normalized name: subcutaneous insulin pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous insulin lispro (12 units)
Trial: 9160847
Drug: Caffeine (average
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (average daily intake)
Trial: 4039870
Drug: Whole-cell pertussis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole-cell pertussis vaccine
Trial: 7949515
Drug: Oral or
RxNorm normalized name: Doral Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral or intranasal formulations of pertussis vaccine
Trial: 22804250
Drug: Dulaglutide 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dulaglutide 0.5 mg
Trial: 31088557
Drug: Regular meetings
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular meetings and follow-ups during treatment period
Trial: 28422846
Drug: Remifentanil (80-2/3*
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil (80-2/3* age) combined with propofol (20-30 mg) for 1 to 2 minutes during ERCP and EST surgery
Trial: 28422846
Drug: Sedative drugs
RxNorm normalized name: MedActive Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sedative drugs not given
Trial: 19304716
Drug: Contrast medium
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contrast medium dosage of 450 mg I/kg of estimated lean body weight (LBW)
Trial: 19304716
Drug: Contrast medium
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contrast medium dosage of 360 mg I/kg of total body weight (TBW)
Trial: 17510758
Drug: D-Cycloserine 50
RxNorm normalized name: D-(+)-cycloserine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-Cycloserine 50 mg
Trial: 15388432
Drug: Ertapenem 1
RxNorm normalized name: ertapenem 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ertapenem 1 g intravenously once daily for 7 days
Trial: 15388432
Drug: Ceftriaxone 2
RxNorm normalized name: ceftriaxone 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone 2 g intravenously once daily for 7 days
Trial: 9806670
Drug: Both HES
RxNorm normalized name: HE-2200
DrugBank: HE-2200 (DB06257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both HES solutions
Trial: 7703045
Drug: Vancomycin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vancomycin (10 mg/kg i.v. every 6 hours, day‐5 to +1)
Trial: 28488142
Drug: Hydrating nail
RxNorm normalized name: FUNGI NAIL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrating nail solution (HNS) applied once a day until grade 2 onycholysis, then twice a day thereafter.
Trial: 24060673
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group receiving screening results and monthly mailings on CVD prevention.
Trial: 16822276
Drug: Lasofoxifene (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lasofoxifene (0.25 mg) with ketoconazole (400 mg daily x 20 days)
Trial: 16822276
Drug: Lasofoxifene (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lasofoxifene (0.25 mg) with fluconazole (400 mg daily x 20 days)
Trial: 16822276
Drug: Lasofoxifene (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lasofoxifene (0.25 mg) with paroxetine (30 mg qd x 21 days)
Trial: 16822276
Drug: Lasofoxifene (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lasofoxifene (0.25 mg) alone
Trial: 798709
Drug: Oxprenolol-Isosorbide dinitrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxprenolol-Isosorbide dinitrate (combination)
Trial: 798709
Drug: Oxprenolol-Nifedipine (combination)
RxNorm normalized name: oxprenolol
DrugBank: Oxprenolol (DB01580)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxprenolol-Nifedipine (combination)
Trial: 29862280
Drug: Continuous Epidural
RxNorm normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous Epidural Infusion (CEI)
Trial: 30782014
Drug: Enhanced treatment-as-usual
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced treatment-as-usual (Control)
Trial: 12598993
Drug: Subcutaneous injection
RxNorm normalized name: EPINEPHRINE 0.3 mg SUBCUTANEOUS INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection of 20 mg of butylscopolamine 10 min before MR examination
Trial: 12598993
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group received only an oral solution
Trial: 8914876
Drug: Losartan 50
RxNorm normalized name: LOSARTAN 50MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan 50 mg/day + Enalapril 10 mg twice a day (group 1)
Trial: 8914876
Drug: Standard-dose Enalapril
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose Enalapril 10 mg twice a day (group 2)
Trial: 8914876
Drug: High-dose Enalapril
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose Enalapril 20 mg twice a day (group 3)
Trial: 26385034
Drug: Early beta-blocker
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early beta-blocker therapy
Trial: 23249415
Drug: Eminol® (grape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eminol® (grape extract) 700 mg
Trial: 19502264
Drug: Infliximab (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infliximab (3 mg/kg body weight at 0, 2, 6 weeks and then q 8 weeks for a total of 24 weeks, total of five doses)
Trial: 17052498
Drug: Vehicle preirradiation
RxNorm normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle preirradiation and postirradiation treatment
Trial: 14519613
Drug: Cognitive-behavioural therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioural therapy (CBT) for depression and parenting skills enhancement
Trial: 8774276
Drug: Endometrial biopsy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endometrial biopsy followed by IM injection of 5,000 IU hCG
Trial: 1727843
Drug: Red light
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Red light therapy
Trial: 1727843
Drug: Infrared light
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infrared light therapy
Trial: 6091474
Drug: Single preoperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single preoperative dose of ceftriaxone
Trial: 6091474
Drug: Multidose cefazolin
RxNorm normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multidose cefazolin (one preoperative and three postoperative doses)
Trial: 26479973
Drug: 3-dose MenACWY-CRM
RxNorm normalized name: Meningococcal oligosaccharide (MenACWY), (MenB), PF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-dose MenACWY-CRM vaccination series
Trial: 26479973
Drug: 4-dose MenACWY-CRM
RxNorm normalized name: Meningococcal oligosaccharide (MenACWY), (MenB), PF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-dose MenACWY-CRM vaccination series
Trial: 26479973
Drug: 3-dose MenACWY-CRM
RxNorm normalized name: Meningococcal oligosaccharide (MenACWY), (MenB), PF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-dose MenACWY-CRM with PCV13
Trial: 26479973
Drug: 4-dose MenACWY-CRM
RxNorm normalized name: Meningococcal oligosaccharide (MenACWY), (MenB), PF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-dose MenACWY-CRM with PCV13
Trial: 25269467
Drug: Dental implants
RxNorm normalized name: Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dental implants placed through skin flaps
Trial: 25269467
Drug: Dental implants
RxNorm normalized name: Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dental implants placed through oral mucosa
Trial: 23096987
Drug: Acellular dermal
RxNorm normalized name: Dermal-Soothe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acellular dermal matrix‐assisted, tissue expander/implant reconstruction
Trial: 23096987
Drug: Submuscular tissue
RxNorm normalized name: tissue respiratory factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Submuscular tissue expander/implant placement
Trial: 12243599
Drug: 5 mL/kg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mL/kg/d of amniotic fluid solution
Trial: 12243599
Drug: 10 mL/kg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mL/kg/d of amniotic fluid solution
Trial: 12243599
Drug: 20 mL/kg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mL/kg/d of amniotic fluid solution
Trial: 30153580
Drug: Phosphorus (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phosphorus (500 mg) with a high-carbohydrate meal
Trial: 21098520
Drug: Ibuprofen plus
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen plus midazolam
Trial: 21098520
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (Acetaminophen alone)
Trial: 3806894
Drug: Intradermal human
RxNorm normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intradermal human diploid cell rabies vaccine (ID HDCV)
Trial: 29241421
Drug: Zinc supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplementation (220 mg zinc sulfate capsules every 72 hours for 1 month)
Trial: 20705223
Drug: Subcutaneous fat
RxNorm normalized name: Sus scrofa subcutaneous fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous fat gain
Trial: 15958805
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg of MLN02 per kilogram
Trial: 15958805
Drug: 2.0 mg
RxNorm normalized name: LORAZEPAM 2.0 mg in 1 mL INTRAVENOUS INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.0 mg of MLN02 per kilogram
Trial: 10325259
Drug: Percutaneous oestradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Percutaneous oestradiol 0.1 mg/day from day 10 after the LH surge until day 4 of the following cycle
Trial: 10325259
Drug: Percutaneous oestradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Percutaneous oestradiol 0.1 mg/day
Trial: 7758304
Drug: Carbopol gel
RxNorm normalized name: Carbopol 981
DrugBank: Carbomer (DB15649)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbopol gel with 10% CaNa2-EDTA
Trial: 7758304
Drug: Carbopol gel
RxNorm normalized name: Carbopol 981
DrugBank: Carbomer (DB15649)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbopol gel without CaNa2-EDTA
Trial: 7758304
Drug: Nickel alloy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nickel alloy without barrier gel
Trial: 6390659
Drug: Ketotifen 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketotifen 0.5 mg X 2 daily
Trial: 6390659
Drug: Ketotifen 1
RxNorm normalized name: ketotifen 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketotifen 1 mg X 2 daily
Trial: 6390659
Drug: Clemastine fumarate
RxNorm normalized name: Clemastine Fumarate
DrugBank: Clemastine (DB00283)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clemastine fumarate 1.34 mg X 2 daily
Trial: 29775083
Drug: Ranitidine 50
RxNorm normalized name: ranitidine 50 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine 50 mg IV every 8 h plus enteral nutrition (EN)
Trial: 29775083
Drug: Ranitidine 50
RxNorm normalized name: ranitidine 50 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine 50 mg IV every 8 h plus EN
Trial: 20220044
Drug: CP‐642,931 (35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CP‐642,931 (35 mg daily for 7 days)
Trial: 7729018
Drug: Medical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical therapy in patients with normal LV systolic function
Trial: 7729018
Drug: Medical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical therapy in patients with normal LV systolic function and right coronary artery stenosis > or = 70%
Trial: 2372155
Drug: 4 ml
RxNorm normalized name: ethanol 1.4 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 ml of 0.5% bupivacaine injected (1 ml every 10 seconds) for spinal anesthesia in group 1 (n = 16)
Trial: 2372155
Drug: 2 ml
RxNorm normalized name: ethanol 2 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 ml of 0.5% bupivacaine injected for continuous spinal anesthesia in group 2 (n = 18)
Trial: 7272174
Drug: Isosorbide dinitrate
RxNorm normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide dinitrate (ISDN) 15 mg
Trial: 7272174
Drug: Isosorbide dinitrate
RxNorm normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide dinitrate (ISDN) single doses
Trial: 7272174
Drug: Isosorbide dinitrate
RxNorm normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide dinitrate (ISDN) chronic dosing
Trial: 7272174
Drug: Isosorbide dinitrate
RxNorm normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide dinitrate (ISDN) 60 mg single dose
Trial: 23247938
Drug: Adalimumab 40
RxNorm normalized name: ADALIMUMAB 40MG/0.8ML INJ,PEN,KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adalimumab 40 mg EOW
Trial: 9374560
Drug: 1500 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1500 mg/kg of RSVIG (RespiGam, MedImmune Inc, Gaithersburg, MD)
Trial: 8193609
Drug: Cilazapril 2.5
RxNorm normalized name: cilazapril 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilazapril 2.5 mg once daily (increased to 5.0 mg if necessary)
Trial: 8193609
Drug: Captopril 25
RxNorm normalized name: captopril 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril 25 mg twice daily (increased to 50 mg if necessary)
Trial: 8193609
Drug: Cilazapril with
RxNorm normalized name: cilazapril
DrugBank: Cilazapril (DB01340)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilazapril with adjunctive hydrochlorothiazide (12.5 mg once daily)
Trial: 8193609
Drug: Captopril with
RxNorm normalized name: Captopril
DrugBank: Captopril (DB01197)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Captopril with adjunctive hydrochlorothiazide (12.5 mg once daily)
Trial: 28569519
Drug: Varenicline plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Varenicline plus smoking cessation counseling and prolonged exposure therapy (VARCC + PE)
Trial: 28147254
Drug: Prolonged exposure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged exposure therapy (PE)
Trial: 23614971
Drug: Bupivacaine 0.125%
RxNorm normalized name: BUPIVACAINE 0.125%/NS INJ 250ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 0.125% and fentanyl 2 μg/mL
Trial: 23614971
Drug: Bupivacaine 0.1%
RxNorm normalized name: BUPIVACAINE 0.1%/NS INJ 250ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 0.1% plus fentanyl 2 μg/mL and epinephrine 2 μg/mL
Trial: 16769782
Drug: Intra-articular glucocorticoid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular glucocorticoid treatment with 20 mg triamcinolone hexacetonide (THA) and 24 hour bed rest
Trial: 16769782
Drug: Intra-articular glucocorticoid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular glucocorticoid treatment with 20 mg triamcinolone hexacetonide (THA) and normal activity
Trial: 15229016
Drug: Medical abortion
RxNorm normalized name: ABSORPTION BASE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical abortion treatment
Trial: 9383230
Drug: Inactivated poliovirus
RxNorm normalized name: Inactivated poliovirus type I
DrugBank: Poliovirus type 1 antigen (formaldehyde inactivated) (DB10795)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated poliovirus vaccine (IPV) at 6, 8 and 14 months after BMT (early group, n = 23)
Trial: 9383230
Drug: Inactivated poliovirus
RxNorm normalized name: Inactivated poliovirus type I
DrugBank: Poliovirus type 1 antigen (formaldehyde inactivated) (DB10795)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated poliovirus vaccine (IPV) at 18, 20 and 26 months after BMT (late group, n = 22)
Trial: 8256243
Drug: Beclomethasone dipropionate
RxNorm normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclomethasone dipropionate (2 mg/day for five months, then 1 mg/day for three months)
Trial: 8256243
Drug: Budesonide (1.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide (1.6 mg/day for five months, then 0.8 mg/day for three months)
Trial: 2863224
Drug: Combined H1-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined H1- and H2-receptor antagonists (clemastine and cimetidine)
Trial: 27030325
Drug: Intravenous prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous prednisolone
Trial: 2863224
Drug: H1-antagonist clemastine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H1-antagonist clemastine
Trial: 26540732
Drug: Intravenous high‐dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous high‐dose methylprednisolone treatment
Trial: 26540732
Drug: Oral high‐dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral high‐dose methylprednisolone treatment
Trial: 20624187
Drug: Cognitive Behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioural Therapy (CBT) group
Trial: 15718838
Drug: Vaccination with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccination with ALVAC‐HIV (vCP1433) and Lipo‐6T vaccines followed by subcutaneous interleukin‐2 (weeks 16, 24, 32)
Trial: 15718838
Drug: Antiviral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiviral therapy alone (control)
Trial: 10695098
Drug: Itraconazole 200
RxNorm normalized name: itraconazole 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itraconazole 200 mg daily for 4 weeks followed by prophylaxis for 24 weeks
Trial: 8457027
Drug: Hypnotic suggestions
RxNorm normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hypnotic suggestions to increase reaction to DCP and decrease reaction to DNCB
Trial: 8457027
Drug: Hypnotic suggestions
RxNorm normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hypnotic suggestions to decrease reaction to DCP and increase reaction to DNCB
Trial: 3026010
Drug: Sulbactam/ampicillin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulbactam/ampicillin plus probenecid (1 g probenecid orally and either one vial of sodium sulbactam/ampicillin or two vials intramuscularly; each vial contained 0.5 g of sodium sulbactam and 1 g of sodium ampicillin)
Trial: 28629269
Drug: Obstacle aquatic
RxNorm normalized name: Mentha aquatica leaf extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Obstacle aquatic therapy
Trial: 28629269
Drug: Traditional aquatic
RxNorm normalized name: Mentha aquatica leaf extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional aquatic therapy
Trial: 23375352
Drug: 1.2 mL
RxNorm normalized name: Mozobil 24 MG in 1.2 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.2 mL 2% lidocaine infused 3 min prior to IUD insertion
Trial: 18521540
Drug: AGI-1067 (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AGI-1067 (300 mg daily for 12 weeks)
Trial: 11237499
Drug: Intra-arterial (i.a.)
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intra-arterial (i.a.) cisplatinum (CDP) in three-drug regimen